Page 1 | Search Results | Blood | American Society of Hematology

1-8 of 8

Sort by

Sort Order Select

Journal Articles

VTE Rates and Safety Analysis of Newly Diagnosed Multiple Myeloma Patients Receiving Carfilzomib-Lenalidomide-Dexamethasone (KRD) with or without Rivaroxaban Prophylaxis

Katrina M Piedra, PharmD, Hani Hassoun, MD, Larry W. Buie, PharmD, BCOP, FASHP, Sean M. Devlin, PhD, Jessica Flynn, BS, Malin Hultcrantz, MD PhD, Alexander M. Lesokhin, MD, Sydney X Lu, MD PhD, Sham Mailankody, MBBS, Urvi A Shah, MD, Eric L Smith, MD PhD, Ola Landgren, MD PhD, Neha Korde, MD, Tim J Peterson, PharmD

Blood (2019) 134 (Supplement_1): 1835.

https://doi.org/10.1182/blood-2019-124403

Published: 2019

Journal Articles

Choice of Hypomethylating Agent (HMA) for Initial Treatment Does Not Influence Outcome or Survival for Therapy-Related Myeloid Neoplasms (t-MN)

Charlene C. Kabel, PharmD, Debra A. Goldman, MS, Larry W. Buie, PharmD, BCOP, FASHP, Virginia M. Klimek, MD

Blood (2019) 134 (Supplement_1): 1718.

https://doi.org/10.1182/blood-2019-129129

Published: 2019

Journal Articles

Effect of Obesity on the Efficacy and Toxicities in Patients Undergoing Autologous Hematopoietic Stem Cell Transplant (AHCT) for Lymphoma

Nicole Pearl, PharmD, Andrew Lin, PharmD, BCOP, Patrick Hilden, MS, Larry W Buie, PharmD, BCOP, FASHP, Kevin Robinson, Molly Maloy, MS, Gunjan L. Shah, MD

Blood (2018) 132 (Supplement 1): 4617.

https://doi.org/10.1182/blood-2018-99-119554

Published: 2018

Journal Articles

Risk of Hyponatremia and Associated Clinical Characteristics in Patients with Acute Lymphoblastic Leukemia after CD19 Targeted Chimeric Antigen Receptor (CAR) T-Cells

Brianne N. Dixon, PharmD, Ryan J. Daley, PharmD, BCOP, Troy Z. Horvat, PharmD, BCOP, Larry W Buie, PharmD, BCOP, FASHP, Meier Hsu, MS, Sheron Latcha, MD, Renier J. Brentjens, MD PhD, Jae H. Park, MD

Blood (2017) 130 (Supplement 1): 3584.

https://doi.org/10.1182/blood.V130.Suppl_1.3584.3584

Published: 2017

Journal Articles

More Intensive Fludarabine/Busulfan (Flu/Bu) Conditioning Regimens Result in Similar Outcomes without Adding Serious Toxicity When Compared to Fludarabine/Melphalan (Flu/Mel) in Patients Undergoing Allogeneic Hematopoietic Cell Transplant (Allo-HCT)

Jeremy Pappacena, PharmD, Valkal Bhatt, PharmD, BCOP, BCPS, Gunjan L. Shah, MD, Patrick Hilden, MS, Molly Maloy, MS, Larry W Buie, PharmD, BCOP, FASHP, Sergio A. Giralt, MD, Michael Scordo, MD

Blood (2017) 130 (Supplement 1): 1950.

https://doi.org/10.1182/blood.V130.Suppl_1.1950.1950

Published: 2017

Journal Articles

Venetoclax Combined with Either a Hypomethylating Agent or Low-Dose Cytarabine Shows Activity in Relapsed and Refractory Myeloid Malignancies

Aaron D Goldberg, MD, Troy Z. Horvat, PharmD, BCOP, Meier Hsu, MS, Sean M. Devlin, PhD, Bernadette M. Cuello, BSN, MSN, NP, RN, Ryan J. Daley, PharmD, BCOP, Amber C. King, PharmD, BCOP, Larry W Buie, PharmD, BCOP, FASHP, Jacob L Glass, MDPhD, Michael J. Mauro, MD, Eytan M. Stein, MD, Ellin Berman, MD, Virginia M. Klimek, MD, Martin S. Tallman, MD

Blood (2017) 130 (Supplement 1): 1353.

https://doi.org/10.1182/blood.V130.Suppl_1.1353.1353

Published: 2017

Journal Articles

Erwinia Asparaginase Safety and Feasibility during Therapy for Acute Lymphoblastic Leukemia in Adult Patients with Pegaspargase Hypersensitivity or Severe Toxicity

Troy Z Horvat, PharmD, BCOP, Joshua J Pecoraro, PharmD, BCOP, Ryan J Daley, PharmD, BCOP, Larry W Buie, PharmD, BCOP, Dan Douer, MD

Blood (2015) 126 (23): 4915.

https://doi.org/10.1182/blood.V126.23.4915.4915

Published: 2015

Journal Articles

Hypoalbuminemia Is Significantly Associated with Increased Clearance Time of High Doses of Methotrexate

Samantha N. Reiss, PharmD, Larry W. Buie, PharmD, BCOP, Nelly G. Adel, PharmD, BCOP, BCPS, Debra A. Goldman, MS, Sean Devlin, PhD, Dan Douer, MD

Blood (2015) 126 (23): 3711.

https://doi.org/10.1182/blood.V126.23.3711.3711

Published: 2015

NARROW

VTE Rates and Safety Analysis of Newly Diagnosed Multiple Myeloma Patients Receiving Carfilzomib-Lenalidomide-Dexamethasone (KRD) with or without Rivaroxaban Prophylaxis

Choice of Hypomethylating Agent (HMA) for Initial Treatment Does Not Influence Outcome or Survival for Therapy-Related Myeloid Neoplasms (t-MN)

Effect of Obesity on the Efficacy and Toxicities in Patients Undergoing Autologous Hematopoietic Stem Cell Transplant (AHCT) for Lymphoma

Risk of Hyponatremia and Associated Clinical Characteristics in Patients with Acute Lymphoblastic Leukemia after CD19 Targeted Chimeric Antigen Receptor (CAR) T-Cells

More Intensive Fludarabine/Busulfan (Flu/Bu) Conditioning Regimens Result in Similar Outcomes without Adding Serious Toxicity When Compared to Fludarabine/Melphalan (Flu/Mel) in Patients Undergoing Allogeneic Hematopoietic Cell Transplant (Allo-HCT)

Venetoclax Combined with Either a Hypomethylating Agent or Low-Dose Cytarabine Shows Activity in Relapsed and Refractory Myeloid Malignancies

Erwinia Asparaginase Safety and Feasibility during Therapy for Acute Lymphoblastic Leukemia in Adult Patients with Pegaspargase Hypersensitivity or Severe Toxicity

Hypoalbuminemia Is Significantly Associated with Increased Clearance Time of High Doses of Methotrexate

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only